nodes	percent_of_prediction	percent_of_DWPC	metapath
Vemurafenib—ABCC1—Dactinomycin—testicular cancer	0.117	0.142	CbGbCtD
Vemurafenib—ABCC1—Epirubicin—testicular cancer	0.0844	0.103	CbGbCtD
Vemurafenib—ABCG2—Dactinomycin—testicular cancer	0.078	0.0953	CbGbCtD
Vemurafenib—ABCC1—Vinblastine—testicular cancer	0.073	0.0892	CbGbCtD
Vemurafenib—ABCC1—Etoposide—testicular cancer	0.0658	0.0804	CbGbCtD
Vemurafenib—ABCG2—Carboplatin—testicular cancer	0.0524	0.0641	CbGbCtD
Vemurafenib—ABCC1—Doxorubicin—testicular cancer	0.0449	0.0548	CbGbCtD
Vemurafenib—ABCG2—Cisplatin—testicular cancer	0.0448	0.0548	CbGbCtD
Vemurafenib—ABCG2—Etoposide—testicular cancer	0.044	0.0538	CbGbCtD
Vemurafenib—ABCC1—Methotrexate—testicular cancer	0.0434	0.0531	CbGbCtD
Vemurafenib—ABCG2—Doxorubicin—testicular cancer	0.03	0.0367	CbGbCtD
Vemurafenib—ABCG2—Methotrexate—testicular cancer	0.0291	0.0355	CbGbCtD
Vemurafenib—ALB—Methotrexate—testicular cancer	0.02	0.0245	CbGbCtD
Vemurafenib—CYP3A4—Ifosfamide—testicular cancer	0.0199	0.0243	CbGbCtD
Vemurafenib—CYP1A2—Etoposide—testicular cancer	0.0181	0.0222	CbGbCtD
Vemurafenib—CYP2D6—Vinblastine—testicular cancer	0.0166	0.0203	CbGbCtD
Vemurafenib—CYP3A4—Vinblastine—testicular cancer	0.0106	0.0129	CbGbCtD
Vemurafenib—CYP2D6—Doxorubicin—testicular cancer	0.0102	0.0125	CbGbCtD
Vemurafenib—CYP3A4—Etoposide—testicular cancer	0.00951	0.0116	CbGbCtD
Vemurafenib—CYP3A4—Doxorubicin—testicular cancer	0.00648	0.00793	CbGbCtD
Vemurafenib—RAF1—embryo—testicular cancer	0.00221	0.108	CbGeAlD
Vemurafenib—RAF1—seminal vesicle—testicular cancer	0.00208	0.101	CbGeAlD
Vemurafenib—BRAF—female gonad—testicular cancer	0.00183	0.0891	CbGeAlD
Vemurafenib—BRAF—testis—testicular cancer	0.00162	0.079	CbGeAlD
Vemurafenib—RAF1—gonad—testicular cancer	0.0015	0.0731	CbGeAlD
Vemurafenib—RAF1—female gonad—testicular cancer	0.00122	0.0594	CbGeAlD
Vemurafenib—BRAF—lymph node—testicular cancer	0.00118	0.0573	CbGeAlD
Vemurafenib—RAF1—testis—testicular cancer	0.00108	0.0527	CbGeAlD
Vemurafenib—ABCC1—seminal vesicle—testicular cancer	0.00104	0.0505	CbGeAlD
Vemurafenib—ABCG2—seminal vesicle—testicular cancer	0.000859	0.0418	CbGeAlD
Vemurafenib—RAF1—lymph node—testicular cancer	0.000784	0.0382	CbGeAlD
Vemurafenib—ALB—testis—testicular cancer	0.000655	0.0319	CbGeAlD
Vemurafenib—ABCC1—female gonad—testicular cancer	0.000609	0.0297	CbGeAlD
Vemurafenib—RAF1—Aryl Hydrocarbon Receptor—HPGDS—testicular cancer	0.00056	0.0292	CbGpPWpGaD
Vemurafenib—BRAF—Bladder Cancer—FGFR3—testicular cancer	0.000554	0.0289	CbGpPWpGaD
Vemurafenib—ORM1—lymph node—testicular cancer	0.000541	0.0263	CbGeAlD
Vemurafenib—ABCC1—testis—testicular cancer	0.00054	0.0263	CbGeAlD
Vemurafenib—ABCC1—Arachidonic acid metabolism—HPGDS—testicular cancer	0.000519	0.0271	CbGpPWpGaD
Vemurafenib—ABCG2—female gonad—testicular cancer	0.000504	0.0246	CbGeAlD
Vemurafenib—BRAF—B Cell Receptor Signaling Pathway—BCL10—testicular cancer	0.000497	0.0259	CbGpPWpGaD
Vemurafenib—ALB—lymph node—testicular cancer	0.000475	0.0231	CbGeAlD
Vemurafenib—RAF1—BCR signaling pathway—BCL10—testicular cancer	0.000462	0.0241	CbGpPWpGaD
Vemurafenib—BRAF—Negative regulation of FGFR signaling—FGFR3—testicular cancer	0.000452	0.0236	CbGpPWpGaD
Vemurafenib—ABCG2—testis—testicular cancer	0.000447	0.0218	CbGeAlD
Vemurafenib—Hypotension—Bleomycin—testicular cancer	0.000405	0.00285	CcSEcCtD
Vemurafenib—Asthenia—Chlorambucil—testicular cancer	0.000402	0.00282	CcSEcCtD
Vemurafenib—Infection—Dactinomycin—testicular cancer	0.000402	0.00282	CcSEcCtD
Vemurafenib—Alopecia—Cisplatin—testicular cancer	0.000398	0.00279	CcSEcCtD
Vemurafenib—Pruritus—Chlorambucil—testicular cancer	0.000397	0.00279	CcSEcCtD
Vemurafenib—Cough—Ifosfamide—testicular cancer	0.000396	0.00278	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Bleomycin—testicular cancer	0.000395	0.00278	CcSEcCtD
Vemurafenib—ABCC1—lymph node—testicular cancer	0.000392	0.0191	CbGeAlD
Vemurafenib—Malnutrition—Cisplatin—testicular cancer	0.000392	0.00275	CcSEcCtD
Vemurafenib—Erythema—Cisplatin—testicular cancer	0.000392	0.00275	CcSEcCtD
Vemurafenib—Erythema multiforme—Etoposide—testicular cancer	0.00039	0.00274	CcSEcCtD
Vemurafenib—Rash maculo-papular—Doxorubicin—testicular cancer	0.000387	0.00272	CcSEcCtD
Vemurafenib—Myalgia—Ifosfamide—testicular cancer	0.000387	0.00272	CcSEcCtD
Vemurafenib—Arthralgia—Ifosfamide—testicular cancer	0.000387	0.00272	CcSEcCtD
Vemurafenib—Eye disorder—Etoposide—testicular cancer	0.000385	0.00271	CcSEcCtD
Vemurafenib—Neoplasm—Doxorubicin—testicular cancer	0.000385	0.0027	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Ifosfamide—testicular cancer	0.000384	0.0027	CcSEcCtD
Vemurafenib—Diarrhoea—Chlorambucil—testicular cancer	0.000383	0.00269	CcSEcCtD
Vemurafenib—Cardiac disorder—Etoposide—testicular cancer	0.000382	0.00269	CcSEcCtD
Vemurafenib—Photosensitivity—Epirubicin—testicular cancer	0.00038	0.00267	CcSEcCtD
Vemurafenib—Hypersensitivity—Vinblastine—testicular cancer	0.000378	0.00266	CcSEcCtD
Vemurafenib—Decreased appetite—Bleomycin—testicular cancer	0.000377	0.00265	CcSEcCtD
Vemurafenib—Angiopathy—Etoposide—testicular cancer	0.000374	0.00263	CcSEcCtD
Vemurafenib—Mediastinal disorder—Etoposide—testicular cancer	0.000371	0.00261	CcSEcCtD
Vemurafenib—Anaphylactic shock—Ifosfamide—testicular cancer	0.000371	0.0026	CcSEcCtD
Vemurafenib—Chills—Etoposide—testicular cancer	0.00037	0.0026	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Dactinomycin—testicular cancer	0.000369	0.00259	CcSEcCtD
Vemurafenib—Asthenia—Vinblastine—testicular cancer	0.000368	0.00259	CcSEcCtD
Vemurafenib—Infection—Ifosfamide—testicular cancer	0.000368	0.00259	CcSEcCtD
Vemurafenib—RAF1—TCR Signaling Pathway—BCL10—testicular cancer	0.000365	0.019	CbGpPWpGaD
Vemurafenib—Alopecia—Etoposide—testicular cancer	0.000364	0.00256	CcSEcCtD
Vemurafenib—Nervous system disorder—Ifosfamide—testicular cancer	0.000364	0.00255	CcSEcCtD
Vemurafenib—Skin disorder—Ifosfamide—testicular cancer	0.00036	0.00253	CcSEcCtD
Vemurafenib—Vomiting—Chlorambucil—testicular cancer	0.000356	0.0025	CcSEcCtD
Vemurafenib—Photosensitivity—Doxorubicin—testicular cancer	0.000352	0.00247	CcSEcCtD
Vemurafenib—Decreased appetite—Dactinomycin—testicular cancer	0.000352	0.00247	CcSEcCtD
Vemurafenib—Diarrhoea—Vinblastine—testicular cancer	0.000351	0.00247	CcSEcCtD
Vemurafenib—Dysgeusia—Etoposide—testicular cancer	0.000351	0.00247	CcSEcCtD
Vemurafenib—Fatigue—Dactinomycin—testicular cancer	0.000349	0.00245	CcSEcCtD
Vemurafenib—Back pain—Etoposide—testicular cancer	0.000347	0.00244	CcSEcCtD
Vemurafenib—RAF1—Signaling events mediated by Stem cell factor receptor (c-Kit)—KITLG—testicular cancer	0.000347	0.0181	CbGpPWpGaD
Vemurafenib—Hypotension—Ifosfamide—testicular cancer	0.000346	0.00243	CcSEcCtD
Vemurafenib—CYP2D6—female gonad—testicular cancer	0.000346	0.0168	CbGeAlD
Vemurafenib—RAF1—B Cell Receptor Signaling Pathway—BCL10—testicular cancer	0.000344	0.0179	CbGpPWpGaD
Vemurafenib—Body temperature increased—Bleomycin—testicular cancer	0.000343	0.00241	CcSEcCtD
Vemurafenib—Dizziness—Vinblastine—testicular cancer	0.00034	0.00239	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Ifosfamide—testicular cancer	0.000338	0.00237	CcSEcCtD
Vemurafenib—Pain in extremity—Epirubicin—testicular cancer	0.000334	0.00235	CcSEcCtD
Vemurafenib—Myalgia—Cisplatin—testicular cancer	0.000333	0.00234	CcSEcCtD
Vemurafenib—Nausea—Chlorambucil—testicular cancer	0.000333	0.00234	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—testicular cancer	0.000331	0.00233	CcSEcCtD
Vemurafenib—Vomiting—Vinblastine—testicular cancer	0.000327	0.00229	CcSEcCtD
Vemurafenib—ABCG2—lymph node—testicular cancer	0.000324	0.0158	CbGeAlD
Vemurafenib—Decreased appetite—Ifosfamide—testicular cancer	0.000322	0.00226	CcSEcCtD
Vemurafenib—Headache—Vinblastine—testicular cancer	0.000322	0.00226	CcSEcCtD
Vemurafenib—Toxic epidermal necrolysis—Methotrexate—testicular cancer	0.000321	0.00226	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Ifosfamide—testicular cancer	0.00032	0.00225	CcSEcCtD
Vemurafenib—Body temperature increased—Dactinomycin—testicular cancer	0.00032	0.00225	CcSEcCtD
Vemurafenib—Fatigue—Ifosfamide—testicular cancer	0.00032	0.00225	CcSEcCtD
Vemurafenib—Anaphylactic shock—Cisplatin—testicular cancer	0.00032	0.00224	CcSEcCtD
Vemurafenib—Hypersensitivity—Bleomycin—testicular cancer	0.00032	0.00224	CcSEcCtD
Vemurafenib—Infection—Cisplatin—testicular cancer	0.000318	0.00223	CcSEcCtD
Vemurafenib—Constipation—Ifosfamide—testicular cancer	0.000317	0.00223	CcSEcCtD
Vemurafenib—Nervous system disorder—Cisplatin—testicular cancer	0.000313	0.0022	CcSEcCtD
Vemurafenib—Cough—Etoposide—testicular cancer	0.000313	0.0022	CcSEcCtD
Vemurafenib—Asthenia—Bleomycin—testicular cancer	0.000311	0.00219	CcSEcCtD
Vemurafenib—Skin disorder—Cisplatin—testicular cancer	0.00031	0.00218	CcSEcCtD
Vemurafenib—Pain in extremity—Doxorubicin—testicular cancer	0.000309	0.00217	CcSEcCtD
Vemurafenib—RAF1—Kit receptor signaling pathway—KITLG—testicular cancer	0.000308	0.0161	CbGpPWpGaD
Vemurafenib—Pruritus—Bleomycin—testicular cancer	0.000307	0.00216	CcSEcCtD
Vemurafenib—CYP2D6—testis—testicular cancer	0.000307	0.0149	CbGeAlD
Vemurafenib—Dry skin—Epirubicin—testicular cancer	0.000306	0.00215	CcSEcCtD
Vemurafenib—Eosinophilia—Methotrexate—testicular cancer	0.000305	0.00214	CcSEcCtD
Vemurafenib—Nausea—Vinblastine—testicular cancer	0.000305	0.00214	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—testicular cancer	0.000303	0.00213	CcSEcCtD
Vemurafenib—Toxic epidermal necrolysis—Epirubicin—testicular cancer	0.000301	0.00211	CcSEcCtD
Vemurafenib—Hypotension—Cisplatin—testicular cancer	0.000299	0.0021	CcSEcCtD
Vemurafenib—Hypersensitivity—Dactinomycin—testicular cancer	0.000298	0.00209	CcSEcCtD
Vemurafenib—Body temperature increased—Ifosfamide—testicular cancer	0.000293	0.00206	CcSEcCtD
Vemurafenib—Anaphylactic shock—Etoposide—testicular cancer	0.000293	0.00206	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Cisplatin—testicular cancer	0.000291	0.00205	CcSEcCtD
Vemurafenib—Infection—Etoposide—testicular cancer	0.000291	0.00204	CcSEcCtD
Vemurafenib—Asthenia—Dactinomycin—testicular cancer	0.00029	0.00204	CcSEcCtD
Vemurafenib—RAF1—FRS2-mediated cascade—FGFR3—testicular cancer	0.00029	0.0151	CbGpPWpGaD
Vemurafenib—Eosinophilia—Epirubicin—testicular cancer	0.000286	0.00201	CcSEcCtD
Vemurafenib—Skin disorder—Etoposide—testicular cancer	0.000284	0.002	CcSEcCtD
Vemurafenib—RAF1—Developmental Biology—PRDM14—testicular cancer	0.000283	0.0148	CbGpPWpGaD
Vemurafenib—Dry skin—Doxorubicin—testicular cancer	0.000283	0.00199	CcSEcCtD
Vemurafenib—Photosensitivity reaction—Methotrexate—testicular cancer	0.000282	0.00198	CcSEcCtD
Vemurafenib—Toxic epidermal necrolysis—Doxorubicin—testicular cancer	0.000278	0.00195	CcSEcCtD
Vemurafenib—Decreased appetite—Cisplatin—testicular cancer	0.000278	0.00195	CcSEcCtD
Vemurafenib—Diarrhoea—Dactinomycin—testicular cancer	0.000277	0.00194	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Cisplatin—testicular cancer	0.000276	0.00194	CcSEcCtD
Vemurafenib—Vomiting—Bleomycin—testicular cancer	0.000276	0.00194	CcSEcCtD
Vemurafenib—Infestation—Methotrexate—testicular cancer	0.000275	0.00193	CcSEcCtD
Vemurafenib—Infestation NOS—Methotrexate—testicular cancer	0.000275	0.00193	CcSEcCtD
Vemurafenib—Hypotension—Etoposide—testicular cancer	0.000274	0.00192	CcSEcCtD
Vemurafenib—Rash—Bleomycin—testicular cancer	0.000274	0.00192	CcSEcCtD
Vemurafenib—Dermatitis—Bleomycin—testicular cancer	0.000273	0.00192	CcSEcCtD
Vemurafenib—Hypersensitivity—Ifosfamide—testicular cancer	0.000273	0.00192	CcSEcCtD
Vemurafenib—Stevens-Johnson syndrome—Methotrexate—testicular cancer	0.000273	0.00192	CcSEcCtD
Vemurafenib—Asthenia—Ifosfamide—testicular cancer	0.000266	0.00187	CcSEcCtD
Vemurafenib—Eosinophilia—Doxorubicin—testicular cancer	0.000264	0.00186	CcSEcCtD
Vemurafenib—Photosensitivity reaction—Epirubicin—testicular cancer	0.000263	0.00185	CcSEcCtD
Vemurafenib—Pruritus—Ifosfamide—testicular cancer	0.000262	0.00184	CcSEcCtD
Vemurafenib—Weight decreased—Epirubicin—testicular cancer	0.000261	0.00183	CcSEcCtD
Vemurafenib—Nausea—Bleomycin—testicular cancer	0.000258	0.00181	CcSEcCtD
Vemurafenib—Infestation—Epirubicin—testicular cancer	0.000257	0.00181	CcSEcCtD
Vemurafenib—Infestation NOS—Epirubicin—testicular cancer	0.000257	0.00181	CcSEcCtD
Vemurafenib—Vomiting—Dactinomycin—testicular cancer	0.000257	0.00181	CcSEcCtD
Vemurafenib—Stevens-Johnson syndrome—Epirubicin—testicular cancer	0.000255	0.00179	CcSEcCtD
Vemurafenib—Rash—Dactinomycin—testicular cancer	0.000255	0.00179	CcSEcCtD
Vemurafenib—Decreased appetite—Etoposide—testicular cancer	0.000255	0.00179	CcSEcCtD
Vemurafenib—Diarrhoea—Ifosfamide—testicular cancer	0.000254	0.00178	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Etoposide—testicular cancer	0.000253	0.00178	CcSEcCtD
Vemurafenib—Body temperature increased—Cisplatin—testicular cancer	0.000253	0.00177	CcSEcCtD
Vemurafenib—Fatigue—Etoposide—testicular cancer	0.000252	0.00177	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Epirubicin—testicular cancer	0.000252	0.00177	CcSEcCtD
Vemurafenib—Constipation—Etoposide—testicular cancer	0.00025	0.00176	CcSEcCtD
Vemurafenib—RAF1—IRS-mediated signalling—STK11—testicular cancer	0.000249	0.013	CbGpPWpGaD
Vemurafenib—RAF1—Retinoblastoma (RB) in Cancer—H2AFZ—testicular cancer	0.000246	0.0128	CbGpPWpGaD
Vemurafenib—Dizziness—Ifosfamide—testicular cancer	0.000245	0.00172	CcSEcCtD
Vemurafenib—Photosensitivity reaction—Doxorubicin—testicular cancer	0.000244	0.00171	CcSEcCtD
Vemurafenib—RAF1—IRS-related events—STK11—testicular cancer	0.000242	0.0126	CbGpPWpGaD
Vemurafenib—Weight decreased—Doxorubicin—testicular cancer	0.000242	0.0017	CcSEcCtD
Vemurafenib—Nausea—Dactinomycin—testicular cancer	0.00024	0.00169	CcSEcCtD
Vemurafenib—RAF1—IRS-related events triggered by IGF1R—STK11—testicular cancer	0.00024	0.0125	CbGpPWpGaD
Vemurafenib—Infestation NOS—Doxorubicin—testicular cancer	0.000238	0.00167	CcSEcCtD
Vemurafenib—Infestation—Doxorubicin—testicular cancer	0.000238	0.00167	CcSEcCtD
Vemurafenib—RAF1—Signaling events mediated by Stem cell factor receptor (c-Kit)—KIT—testicular cancer	0.000236	0.0123	CbGpPWpGaD
Vemurafenib—Stevens-Johnson syndrome—Doxorubicin—testicular cancer	0.000236	0.00166	CcSEcCtD
Vemurafenib—Vomiting—Ifosfamide—testicular cancer	0.000236	0.00166	CcSEcCtD
Vemurafenib—Hypersensitivity—Cisplatin—testicular cancer	0.000235	0.00165	CcSEcCtD
Vemurafenib—Rash—Ifosfamide—testicular cancer	0.000234	0.00164	CcSEcCtD
Vemurafenib—RAF1—IGF1R signaling cascade—STK11—testicular cancer	0.000234	0.0122	CbGpPWpGaD
Vemurafenib—RAF1—Insulin receptor signalling cascade—STK11—testicular cancer	0.000234	0.0122	CbGpPWpGaD
Vemurafenib—Dermatitis—Ifosfamide—testicular cancer	0.000234	0.00164	CcSEcCtD
Vemurafenib—Erythema multiforme—Methotrexate—testicular cancer	0.000233	0.00164	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Doxorubicin—testicular cancer	0.000233	0.00164	CcSEcCtD
Vemurafenib—Body temperature increased—Etoposide—testicular cancer	0.000231	0.00163	CcSEcCtD
Vemurafenib—Eye disorder—Methotrexate—testicular cancer	0.000231	0.00162	CcSEcCtD
Vemurafenib—Asthenia—Cisplatin—testicular cancer	0.000229	0.00161	CcSEcCtD
Vemurafenib—Cardiac disorder—Methotrexate—testicular cancer	0.000229	0.00161	CcSEcCtD
Vemurafenib—Oedema peripheral—Epirubicin—testicular cancer	0.000228	0.0016	CcSEcCtD
Vemurafenib—BRAF—Integrated Breast Cancer Pathway—STK11—testicular cancer	0.000227	0.0119	CbGpPWpGaD
Vemurafenib—Connective tissue disorder—Epirubicin—testicular cancer	0.000227	0.00159	CcSEcCtD
Vemurafenib—Angiopathy—Methotrexate—testicular cancer	0.000224	0.00157	CcSEcCtD
Vemurafenib—Mediastinal disorder—Methotrexate—testicular cancer	0.000222	0.00156	CcSEcCtD
Vemurafenib—Chills—Methotrexate—testicular cancer	0.000221	0.00156	CcSEcCtD
Vemurafenib—Nausea—Ifosfamide—testicular cancer	0.00022	0.00155	CcSEcCtD
Vemurafenib—Diarrhoea—Cisplatin—testicular cancer	0.000219	0.00154	CcSEcCtD
Vemurafenib—Erythema multiforme—Epirubicin—testicular cancer	0.000218	0.00153	CcSEcCtD
Vemurafenib—Alopecia—Methotrexate—testicular cancer	0.000218	0.00153	CcSEcCtD
Vemurafenib—Eye disorder—Epirubicin—testicular cancer	0.000216	0.00152	CcSEcCtD
Vemurafenib—Hypersensitivity—Etoposide—testicular cancer	0.000216	0.00152	CcSEcCtD
Vemurafenib—Erythema—Methotrexate—testicular cancer	0.000215	0.00151	CcSEcCtD
Vemurafenib—Malnutrition—Methotrexate—testicular cancer	0.000215	0.00151	CcSEcCtD
Vemurafenib—Cardiac disorder—Epirubicin—testicular cancer	0.000214	0.00151	CcSEcCtD
Vemurafenib—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—testicular cancer	0.000213	0.0111	CbGpPWpGaD
Vemurafenib—RAF1—Fc epsilon receptor (FCERI) signaling—BCL10—testicular cancer	0.000212	0.0111	CbGpPWpGaD
Vemurafenib—CYP1A2—Aryl Hydrocarbon Receptor—HPGDS—testicular cancer	0.000211	0.011	CbGpPWpGaD
Vemurafenib—Oedema peripheral—Doxorubicin—testicular cancer	0.000211	0.00148	CcSEcCtD
Vemurafenib—RAF1—Kit receptor signaling pathway—KIT—testicular cancer	0.00021	0.011	CbGpPWpGaD
Vemurafenib—Dysgeusia—Methotrexate—testicular cancer	0.00021	0.00148	CcSEcCtD
Vemurafenib—Asthenia—Etoposide—testicular cancer	0.00021	0.00148	CcSEcCtD
Vemurafenib—Connective tissue disorder—Doxorubicin—testicular cancer	0.00021	0.00148	CcSEcCtD
Vemurafenib—Angiopathy—Epirubicin—testicular cancer	0.00021	0.00147	CcSEcCtD
Vemurafenib—Mediastinal disorder—Epirubicin—testicular cancer	0.000208	0.00146	CcSEcCtD
Vemurafenib—Back pain—Methotrexate—testicular cancer	0.000208	0.00146	CcSEcCtD
Vemurafenib—ALB—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000208	0.0108	CbGpPWpGaD
Vemurafenib—Chills—Epirubicin—testicular cancer	0.000207	0.00146	CcSEcCtD
Vemurafenib—Pruritus—Etoposide—testicular cancer	0.000207	0.00146	CcSEcCtD
Vemurafenib—Alopecia—Epirubicin—testicular cancer	0.000204	0.00143	CcSEcCtD
Vemurafenib—Vomiting—Cisplatin—testicular cancer	0.000203	0.00143	CcSEcCtD
Vemurafenib—Erythema multiforme—Doxorubicin—testicular cancer	0.000202	0.00142	CcSEcCtD
Vemurafenib—Rash—Cisplatin—testicular cancer	0.000202	0.00142	CcSEcCtD
Vemurafenib—Dermatitis—Cisplatin—testicular cancer	0.000201	0.00141	CcSEcCtD
Vemurafenib—Malnutrition—Epirubicin—testicular cancer	0.000201	0.00141	CcSEcCtD
Vemurafenib—Erythema—Epirubicin—testicular cancer	0.000201	0.00141	CcSEcCtD
Vemurafenib—Diarrhoea—Etoposide—testicular cancer	0.0002	0.00141	CcSEcCtD
Vemurafenib—Eye disorder—Doxorubicin—testicular cancer	0.0002	0.0014	CcSEcCtD
Vemurafenib—BRAF—Signaling by FGFR—KITLG—testicular cancer	0.000199	0.0104	CbGpPWpGaD
Vemurafenib—Cardiac disorder—Doxorubicin—testicular cancer	0.000198	0.00139	CcSEcCtD
Vemurafenib—CYP1A2—Arachidonic acid metabolism—HPGDS—testicular cancer	0.000197	0.0103	CbGpPWpGaD
Vemurafenib—Dysgeusia—Epirubicin—testicular cancer	0.000197	0.00138	CcSEcCtD
Vemurafenib—RAF1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000196	0.0102	CbGpPWpGaD
Vemurafenib—Back pain—Epirubicin—testicular cancer	0.000195	0.00137	CcSEcCtD
Vemurafenib—ABCC1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000194	0.0101	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by Insulin receptor—STK11—testicular cancer	0.000194	0.0101	CbGpPWpGaD
Vemurafenib—Angiopathy—Doxorubicin—testicular cancer	0.000194	0.00136	CcSEcCtD
Vemurafenib—Dizziness—Etoposide—testicular cancer	0.000194	0.00136	CcSEcCtD
Vemurafenib—Mediastinal disorder—Doxorubicin—testicular cancer	0.000193	0.00135	CcSEcCtD
Vemurafenib—Chills—Doxorubicin—testicular cancer	0.000192	0.00135	CcSEcCtD
Vemurafenib—Nausea—Cisplatin—testicular cancer	0.00019	0.00133	CcSEcCtD
Vemurafenib—Alopecia—Doxorubicin—testicular cancer	0.000189	0.00133	CcSEcCtD
Vemurafenib—Cough—Methotrexate—testicular cancer	0.000188	0.00132	CcSEcCtD
Vemurafenib—Vomiting—Etoposide—testicular cancer	0.000186	0.00131	CcSEcCtD
Vemurafenib—Malnutrition—Doxorubicin—testicular cancer	0.000186	0.00131	CcSEcCtD
Vemurafenib—Erythema—Doxorubicin—testicular cancer	0.000186	0.00131	CcSEcCtD
Vemurafenib—BRAF—Signaling by FGFR in disease—KITLG—testicular cancer	0.000185	0.00966	CbGpPWpGaD
Vemurafenib—Rash—Etoposide—testicular cancer	0.000185	0.0013	CcSEcCtD
Vemurafenib—Dermatitis—Etoposide—testicular cancer	0.000184	0.0013	CcSEcCtD
Vemurafenib—Headache—Etoposide—testicular cancer	0.000183	0.00129	CcSEcCtD
Vemurafenib—Myalgia—Methotrexate—testicular cancer	0.000183	0.00129	CcSEcCtD
Vemurafenib—Arthralgia—Methotrexate—testicular cancer	0.000183	0.00129	CcSEcCtD
Vemurafenib—Dysgeusia—Doxorubicin—testicular cancer	0.000182	0.00128	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000182	0.00128	CcSEcCtD
Vemurafenib—Back pain—Doxorubicin—testicular cancer	0.00018	0.00126	CcSEcCtD
Vemurafenib—RAF1—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	0.000179	0.00935	CbGpPWpGaD
Vemurafenib—Cough—Epirubicin—testicular cancer	0.000175	0.00123	CcSEcCtD
Vemurafenib—Anaphylactic shock—Methotrexate—testicular cancer	0.000175	0.00123	CcSEcCtD
Vemurafenib—Infection—Methotrexate—testicular cancer	0.000174	0.00122	CcSEcCtD
Vemurafenib—Nausea—Etoposide—testicular cancer	0.000174	0.00122	CcSEcCtD
Vemurafenib—Nervous system disorder—Methotrexate—testicular cancer	0.000172	0.00121	CcSEcCtD
Vemurafenib—Myalgia—Epirubicin—testicular cancer	0.000171	0.0012	CcSEcCtD
Vemurafenib—Arthralgia—Epirubicin—testicular cancer	0.000171	0.0012	CcSEcCtD
Vemurafenib—RAF1—IRS-mediated signalling—FGFR3—testicular cancer	0.000171	0.00893	CbGpPWpGaD
Vemurafenib—ABCG2—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000171	0.00892	CbGpPWpGaD
Vemurafenib—RAF1—AGE/RAGE pathway—MMP2—testicular cancer	0.00017	0.00889	CbGpPWpGaD
Vemurafenib—Skin disorder—Methotrexate—testicular cancer	0.00017	0.0012	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.00017	0.00119	CcSEcCtD
Vemurafenib—RAF1—IRS-related events—FGFR3—testicular cancer	0.000166	0.00868	CbGpPWpGaD
Vemurafenib—RAF1—IRS-related events triggered by IGF1R—FGFR3—testicular cancer	0.000165	0.00861	CbGpPWpGaD
Vemurafenib—Anaphylactic shock—Epirubicin—testicular cancer	0.000164	0.00115	CcSEcCtD
Vemurafenib—BRAF—NGF signalling via TRKA from the plasma membrane—KITLG—testicular cancer	0.000164	0.00855	CbGpPWpGaD
Vemurafenib—Hypotension—Methotrexate—testicular cancer	0.000164	0.00115	CcSEcCtD
Vemurafenib—Infection—Epirubicin—testicular cancer	0.000163	0.00115	CcSEcCtD
Vemurafenib—Cough—Doxorubicin—testicular cancer	0.000162	0.00114	CcSEcCtD
Vemurafenib—Nervous system disorder—Epirubicin—testicular cancer	0.000161	0.00113	CcSEcCtD
Vemurafenib—RAF1—Insulin receptor signalling cascade—FGFR3—testicular cancer	0.000161	0.00838	CbGpPWpGaD
Vemurafenib—RAF1—IGF1R signaling cascade—FGFR3—testicular cancer	0.000161	0.00838	CbGpPWpGaD
Vemurafenib—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.00016	0.00112	CcSEcCtD
Vemurafenib—Skin disorder—Epirubicin—testicular cancer	0.000159	0.00112	CcSEcCtD
Vemurafenib—Arthralgia—Doxorubicin—testicular cancer	0.000158	0.00111	CcSEcCtD
Vemurafenib—Myalgia—Doxorubicin—testicular cancer	0.000158	0.00111	CcSEcCtD
Vemurafenib—BRAF—Regulation of Actin Cytoskeleton—FGFR3—testicular cancer	0.000158	0.00824	CbGpPWpGaD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000157	0.00111	CcSEcCtD
Vemurafenib—RAF1—Signaling by SCF-KIT—KITLG—testicular cancer	0.000154	0.00801	CbGpPWpGaD
Vemurafenib—Hypotension—Epirubicin—testicular cancer	0.000153	0.00108	CcSEcCtD
Vemurafenib—Decreased appetite—Methotrexate—testicular cancer	0.000152	0.00107	CcSEcCtD
Vemurafenib—Anaphylactic shock—Doxorubicin—testicular cancer	0.000152	0.00107	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000151	0.00106	CcSEcCtD
Vemurafenib—Fatigue—Methotrexate—testicular cancer	0.000151	0.00106	CcSEcCtD
Vemurafenib—Infection—Doxorubicin—testicular cancer	0.000151	0.00106	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.00015	0.00105	CcSEcCtD
Vemurafenib—Nervous system disorder—Doxorubicin—testicular cancer	0.000149	0.00105	CcSEcCtD
Vemurafenib—BRAF—Signaling by FGFR—FGFR3—testicular cancer	0.000148	0.0077	CbGpPWpGaD
Vemurafenib—Skin disorder—Doxorubicin—testicular cancer	0.000148	0.00104	CcSEcCtD
Vemurafenib—RAF1—Downstream signaling of activated FGFR—KITLG—testicular cancer	0.000147	0.00767	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by ERBB4—KITLG—testicular cancer	0.000145	0.00755	CbGpPWpGaD
Vemurafenib—Decreased appetite—Epirubicin—testicular cancer	0.000143	0.001	CcSEcCtD
Vemurafenib—Hypotension—Doxorubicin—testicular cancer	0.000142	0.000997	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000142	0.000995	CcSEcCtD
Vemurafenib—Fatigue—Epirubicin—testicular cancer	0.000142	0.000994	CcSEcCtD
Vemurafenib—Constipation—Epirubicin—testicular cancer	0.00014	0.000986	CcSEcCtD
Vemurafenib—Body temperature increased—Methotrexate—testicular cancer	0.000139	0.000974	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.000138	0.000972	CcSEcCtD
Vemurafenib—RAF1—Downstream signal transduction—KITLG—testicular cancer	0.000138	0.00721	CbGpPWpGaD
Vemurafenib—BRAF—Signaling by FGFR in disease—FGFR3—testicular cancer	0.000138	0.00718	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by FGFR—KITLG—testicular cancer	0.000137	0.00717	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by ERBB2—KITLG—testicular cancer	0.000137	0.00714	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 signaling—KITLG—testicular cancer	0.000136	0.0071	CbGpPWpGaD
Vemurafenib—BRAF—Signaling by FGFR—KIT—testicular cancer	0.000136	0.00707	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by Insulin receptor—FGFR3—testicular cancer	0.000133	0.00696	CbGpPWpGaD
Vemurafenib—Decreased appetite—Doxorubicin—testicular cancer	0.000132	0.000927	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000131	0.000921	CcSEcCtD
Vemurafenib—Fatigue—Doxorubicin—testicular cancer	0.000131	0.00092	CcSEcCtD
Vemurafenib—RAF1—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	0.00013	0.00679	CbGpPWpGaD
Vemurafenib—Constipation—Doxorubicin—testicular cancer	0.00013	0.000912	CcSEcCtD
Vemurafenib—Body temperature increased—Epirubicin—testicular cancer	0.00013	0.000911	CcSEcCtD
Vemurafenib—Hypersensitivity—Methotrexate—testicular cancer	0.000129	0.000908	CcSEcCtD
Vemurafenib—RAF1—Signaling by FGFR in disease—KITLG—testicular cancer	0.000128	0.00668	CbGpPWpGaD
Vemurafenib—RAF1—Fc epsilon receptor (FCERI) signaling—KITLG—testicular cancer	0.000128	0.00668	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 interactions—KITLG—testicular cancer	0.000128	0.00668	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by EGFR—KITLG—testicular cancer	0.000127	0.00662	CbGpPWpGaD
Vemurafenib—BRAF—Signaling by FGFR in disease—KIT—testicular cancer	0.000126	0.00659	CbGpPWpGaD
Vemurafenib—BRAF—Signaling by NGF—KITLG—testicular cancer	0.000126	0.00658	CbGpPWpGaD
Vemurafenib—Asthenia—Methotrexate—testicular cancer	0.000126	0.000884	CcSEcCtD
Vemurafenib—RAF1—Signaling by EGFR in Cancer—KITLG—testicular cancer	0.000126	0.00656	CbGpPWpGaD
Vemurafenib—CYP1A2—Phase II conjugation—HPGDS—testicular cancer	0.000125	0.00654	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by PDGF—KITLG—testicular cancer	0.000125	0.00653	CbGpPWpGaD
Vemurafenib—Pruritus—Methotrexate—testicular cancer	0.000124	0.000872	CcSEcCtD
Vemurafenib—BRAF—NGF signalling via TRKA from the plasma membrane—FGFR3—testicular cancer	0.000122	0.00636	CbGpPWpGaD
Vemurafenib—Hypersensitivity—Epirubicin—testicular cancer	0.000121	0.000849	CcSEcCtD
Vemurafenib—Body temperature increased—Doxorubicin—testicular cancer	0.00012	0.000843	CcSEcCtD
Vemurafenib—Diarrhoea—Methotrexate—testicular cancer	0.00012	0.000843	CcSEcCtD
Vemurafenib—Asthenia—Epirubicin—testicular cancer	0.000118	0.000827	CcSEcCtD
Vemurafenib—Pruritus—Epirubicin—testicular cancer	0.000116	0.000816	CcSEcCtD
Vemurafenib—Dizziness—Methotrexate—testicular cancer	0.000116	0.000815	CcSEcCtD
Vemurafenib—RAF1—Signaling by SCF-KIT—FGFR3—testicular cancer	0.000114	0.00596	CbGpPWpGaD
Vemurafenib—RAF1—NGF signalling via TRKA from the plasma membrane—KITLG—testicular cancer	0.000113	0.00592	CbGpPWpGaD
Vemurafenib—Diarrhoea—Epirubicin—testicular cancer	0.000112	0.000789	CcSEcCtD
Vemurafenib—Hypersensitivity—Doxorubicin—testicular cancer	0.000112	0.000786	CcSEcCtD
Vemurafenib—BRAF—NGF signalling via TRKA from the plasma membrane—KIT—testicular cancer	0.000112	0.00584	CbGpPWpGaD
Vemurafenib—Vomiting—Methotrexate—testicular cancer	0.000112	0.000783	CcSEcCtD
Vemurafenib—Rash—Methotrexate—testicular cancer	0.000111	0.000777	CcSEcCtD
Vemurafenib—Dermatitis—Methotrexate—testicular cancer	0.00011	0.000776	CcSEcCtD
Vemurafenib—Headache—Methotrexate—testicular cancer	0.00011	0.000772	CcSEcCtD
Vemurafenib—RAF1—Downstream signaling of activated FGFR—FGFR3—testicular cancer	0.000109	0.0057	CbGpPWpGaD
Vemurafenib—RAF1—Regulation of Actin Cytoskeleton—FGFR3—testicular cancer	0.000109	0.0057	CbGpPWpGaD
Vemurafenib—Asthenia—Doxorubicin—testicular cancer	0.000109	0.000765	CcSEcCtD
Vemurafenib—Dizziness—Epirubicin—testicular cancer	0.000109	0.000762	CcSEcCtD
Vemurafenib—RAF1—Signaling by GPCR—INSL3—testicular cancer	0.000108	0.00562	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by ERBB4—FGFR3—testicular cancer	0.000108	0.00561	CbGpPWpGaD
Vemurafenib—Pruritus—Doxorubicin—testicular cancer	0.000107	0.000755	CcSEcCtD
Vemurafenib—ALB—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000106	0.00551	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by SCF-KIT—KIT—testicular cancer	0.000105	0.00547	CbGpPWpGaD
Vemurafenib—Vomiting—Epirubicin—testicular cancer	0.000104	0.000733	CcSEcCtD
Vemurafenib—Nausea—Methotrexate—testicular cancer	0.000104	0.000732	CcSEcCtD
Vemurafenib—Diarrhoea—Doxorubicin—testicular cancer	0.000104	0.00073	CcSEcCtD
Vemurafenib—Rash—Epirubicin—testicular cancer	0.000103	0.000727	CcSEcCtD
Vemurafenib—Dermatitis—Epirubicin—testicular cancer	0.000103	0.000726	CcSEcCtD
Vemurafenib—Headache—Epirubicin—testicular cancer	0.000103	0.000722	CcSEcCtD
Vemurafenib—RAF1—Downstream signal transduction—FGFR3—testicular cancer	0.000103	0.00536	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by FGFR—FGFR3—testicular cancer	0.000102	0.00533	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by ERBB2—FGFR3—testicular cancer	0.000102	0.0053	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 signaling—FGFR3—testicular cancer	0.000101	0.00528	CbGpPWpGaD
Vemurafenib—Dizziness—Doxorubicin—testicular cancer	0.0001	0.000705	CcSEcCtD
Vemurafenib—RAF1—Downstream signaling of activated FGFR—KIT—testicular cancer	0.0001	0.00523	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by ERBB4—KIT—testicular cancer	9.87e-05	0.00515	CbGpPWpGaD
Vemurafenib—Nausea—Epirubicin—testicular cancer	9.75e-05	0.000685	CcSEcCtD
Vemurafenib—Vomiting—Doxorubicin—testicular cancer	9.66e-05	0.000678	CcSEcCtD
Vemurafenib—Rash—Doxorubicin—testicular cancer	9.58e-05	0.000673	CcSEcCtD
Vemurafenib—Dermatitis—Doxorubicin—testicular cancer	9.57e-05	0.000672	CcSEcCtD
Vemurafenib—RAF1—Signaling by FGFR in disease—FGFR3—testicular cancer	9.52e-05	0.00497	CbGpPWpGaD
Vemurafenib—RAF1—Fc epsilon receptor (FCERI) signaling—FGFR3—testicular cancer	9.52e-05	0.00497	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 interactions—FGFR3—testicular cancer	9.52e-05	0.00497	CbGpPWpGaD
Vemurafenib—Headache—Doxorubicin—testicular cancer	9.51e-05	0.000668	CcSEcCtD
Vemurafenib—RAF1—Signaling by EGFR—FGFR3—testicular cancer	9.43e-05	0.00492	CbGpPWpGaD
Vemurafenib—RAF1—Downstream signal transduction—KIT—testicular cancer	9.43e-05	0.00492	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by FGFR—KIT—testicular cancer	9.38e-05	0.00489	CbGpPWpGaD
Vemurafenib—BRAF—Signaling by NGF—FGFR3—testicular cancer	9.37e-05	0.00489	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by EGFR in Cancer—FGFR3—testicular cancer	9.35e-05	0.00488	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by ERBB2—KIT—testicular cancer	9.33e-05	0.00487	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by PDGF—FGFR3—testicular cancer	9.31e-05	0.00486	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 signaling—KIT—testicular cancer	9.29e-05	0.00485	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—INSL3—testicular cancer	9.2e-05	0.0048	CbGpPWpGaD
Vemurafenib—Nausea—Doxorubicin—testicular cancer	9.02e-05	0.000634	CcSEcCtD
Vemurafenib—RAF1—Signaling by FGFR in disease—KIT—testicular cancer	8.74e-05	0.00456	CbGpPWpGaD
Vemurafenib—RAF1—Fc epsilon receptor (FCERI) signaling—KIT—testicular cancer	8.74e-05	0.00456	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 interactions—KIT—testicular cancer	8.74e-05	0.00456	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—KITLG—testicular cancer	8.72e-05	0.00455	CbGpPWpGaD
Vemurafenib—CYP2D6—Biological oxidations—HPGDS—testicular cancer	8.66e-05	0.00452	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by EGFR—KIT—testicular cancer	8.66e-05	0.00452	CbGpPWpGaD
Vemurafenib—BRAF—Signaling by NGF—KIT—testicular cancer	8.6e-05	0.00449	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by EGFR in Cancer—KIT—testicular cancer	8.58e-05	0.00448	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by PDGF—KIT—testicular cancer	8.55e-05	0.00446	CbGpPWpGaD
Vemurafenib—RAF1—NGF signalling via TRKA from the plasma membrane—FGFR3—testicular cancer	8.43e-05	0.0044	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—BCL10—testicular cancer	8.25e-05	0.00431	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—BCL10—testicular cancer	7.92e-05	0.00413	CbGpPWpGaD
Vemurafenib—RAF1—NGF signalling via TRKA from the plasma membrane—KIT—testicular cancer	7.74e-05	0.00404	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	7.42e-05	0.00387	CbGpPWpGaD
Vemurafenib—CYP1A2—Biological oxidations—HPGDS—testicular cancer	7.34e-05	0.00383	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—FGFR3—testicular cancer	6.48e-05	0.00338	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—INSL3—testicular cancer	6.36e-05	0.00332	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—KIT—testicular cancer	5.95e-05	0.00311	CbGpPWpGaD
Vemurafenib—CYP3A4—Biological oxidations—HPGDS—testicular cancer	5.66e-05	0.00295	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—KITLG—testicular cancer	4.98e-05	0.0026	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—BCL10—testicular cancer	4.81e-05	0.00251	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—KITLG—testicular cancer	4.78e-05	0.00249	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—MMP2—testicular cancer	4.77e-05	0.00249	CbGpPWpGaD
Vemurafenib—BRAF—Disease—H2AFZ—testicular cancer	4.2e-05	0.00219	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	4.03e-05	0.0021	CbGpPWpGaD
Vemurafenib—BRAF—Disease—KITLG—testicular cancer	3.87e-05	0.00202	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—FGFR3—testicular cancer	3.7e-05	0.00193	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—FGFR3—testicular cancer	3.55e-05	0.00185	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—MMP2—testicular cancer	3.41e-05	0.00178	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—KIT—testicular cancer	3.4e-05	0.00177	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—HPGDS—testicular cancer	3.3e-05	0.00172	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—KIT—testicular cancer	3.26e-05	0.0017	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—H2AFZ—testicular cancer	2.94e-05	0.00154	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—STK11—testicular cancer	2.93e-05	0.00153	CbGpPWpGaD
Vemurafenib—RAF1—Disease—H2AFZ—testicular cancer	2.91e-05	0.00152	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—HPGDS—testicular cancer	2.91e-05	0.00152	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—KITLG—testicular cancer	2.9e-05	0.00151	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—H2AFZ—testicular cancer	2.88e-05	0.0015	CbGpPWpGaD
Vemurafenib—BRAF—Disease—FGFR3—testicular cancer	2.87e-05	0.0015	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	2.82e-05	0.00147	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—KITLG—testicular cancer	2.71e-05	0.00141	CbGpPWpGaD
Vemurafenib—RAF1—Disease—KITLG—testicular cancer	2.68e-05	0.0014	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—KITLG—testicular cancer	2.65e-05	0.00138	CbGpPWpGaD
Vemurafenib—BRAF—Disease—KIT—testicular cancer	2.64e-05	0.00138	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—STK11—testicular cancer	2.4e-05	0.00125	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—FGFR3—testicular cancer	2.15e-05	0.00112	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—STK11—testicular cancer	2.11e-05	0.0011	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—H2AFZ—testicular cancer	2.04e-05	0.00106	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—STK11—testicular cancer	2.03e-05	0.00106	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—FGFR3—testicular cancer	2.01e-05	0.00105	CbGpPWpGaD
Vemurafenib—RAF1—Disease—FGFR3—testicular cancer	1.99e-05	0.00104	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—KIT—testicular cancer	1.98e-05	0.00103	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—FGFR3—testicular cancer	1.97e-05	0.00103	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—KITLG—testicular cancer	1.87e-05	0.000978	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—KIT—testicular cancer	1.85e-05	0.000964	CbGpPWpGaD
Vemurafenib—RAF1—Disease—KIT—testicular cancer	1.83e-05	0.000953	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—KIT—testicular cancer	1.81e-05	0.000944	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—HPGDS—testicular cancer	1.79e-05	0.000936	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—HPGDS—testicular cancer	1.48e-05	0.000773	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—FGFR3—testicular cancer	1.39e-05	0.000727	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—STK11—testicular cancer	1.3e-05	0.00068	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—KIT—testicular cancer	1.28e-05	0.000667	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—HPGDS—testicular cancer	1.25e-05	0.000655	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—STK11—testicular cancer	1.08e-05	0.000561	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—HPGDS—testicular cancer	9.68e-06	0.000505	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—STK11—testicular cancer	9.12e-06	0.000476	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—STK11—testicular cancer	7.04e-06	0.000367	CbGpPWpGaD
